glp-1 medications market 2025 Agonists Weight Loss Drugs Report, 2025-2030 GLP-1 Receptor Agonist Market Size

A solid choice if heart palpitations are your primary concern

Exenatide, the first GLP-1RA approved in 2005, demonstrated clinical efficacy but its low homology with human GLP-1 and gastrointestinal side effects restricted widespread use (Muttenthaler et al., 2021)

A 2026 study published in Cardiovascular Diabetology found an association between GLP-1 use and lower risks of heart attack, stroke, heart failure and premature death among high-risk patients building on earlier evidence from Novo Nordisk's SELECT trial, which showed that Wegovy reduced major adverse cardiovascular events versus placebo in people with established heart disease

You may unsubscribe at any time

Early Research in Autoimmune Disease & Fibromyalgia What It Shows and Why Its Limited Fibromyalgia: Early Signals, No Conclusions Some observational reports describe symptom improvements (pain, fatigue, opioid use) in people taking GLP-1 medications, but limitations are consistent: non-randomized design, small samples, and confounding from weight loss, sleep, and metabolic improvements